Ivermectin, a specific drug for infectious diseases caused by parasites such as blindness, was not effective even when administered to patients with the new coronavirus. ” announced.
It is said that it will give up applying for approval as a treatment for the new corona.
Kowa held a press conference in Tokyo on the 26th and announced the results of the clinical trial.
According to that, from November last year to last month, the clinical trial was conducted on 1030 mild corona patients aged 12 and over, with a group taking ivermectin once a day for 3 days and a group taking placebo. They were compared in such a way that neither the patient nor the doctor knew which one was being administered.
As a result, in all groups, symptoms such as fever and sore throat subsided about 4 days after administration, and no efficacy was found in improving the drug, so the company applied for approval as a therapeutic drug for the new corona. announced that it would discontinue
Ivermectin was developed based on the research of Satoshi Omura, Distinguished Emeritus Professor of Kitasato University, who won the Nobel Prize in Physiology or Medicine. Research has been conducted in various countries to see if there is, but in March this year, a research group in Brazil and other countries announced the results of a clinical trial that had no effect on reducing the risk of hospitalization.
President Yoshihiro Miwa said, "The entire company has been involved in clinical trials, but we cannot consider applying for approval based on these results. We would like to accept the results."